Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Core Viewpoint - Anavex Life Sciences Corp. is set to release its financial results for the first fiscal quarter on February 12, 2025, and will host a conference call to discuss these results and the company's growth strategy [1][2]. Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome [1][4]. - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [4]. - ANAVEX3-71 is another promising drug candidate targeting SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity against Alzheimer's disease in preclinical trials [4]. Conference Call Details - The conference call will take place on February 12, 2025, at 8:30 am ET, and will include a question-and-answer session following management's remarks [2][3]. - Participants can access the call via a live webcast on Anavex's website or by dialing a specific number for U.S. participants [3].